The Modified Ottawa Score and Clinical Events in Hospitalized Patients with Cancer-Associated Thrombosis from the Swiss VTE Registry

Adriano Alatri; Lucia Mazzolai; Nils Kucher; Drahomir Aujesky; Jürg H. Beer; Thomas Baldi; Martin Banyai; Daniel Hayoz; Thomas Kaeslin; Wolfgang Korte; Robert Escher; Marc Husmann; Beat Frauchiger; Rolf P. Engelberger; Iris Baumgartner; David Spirk

doi:10.1055/s-0037-1604086

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2017; 43(08): 871-876
DOI: 10.1055/s-0037-1604086

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Modified Ottawa Score and Clinical Events in Hospitalized Patients with Cancer-Associated Thrombosis from the Swiss VTE Registry

Adriano Alatri

¹Division of Angiology, Lausanne University Hospital, Lausanne, Switzerland

,

Lucia Mazzolai

¹Division of Angiology, Lausanne University Hospital, Lausanne, Switzerland

,

Nils Kucher

²Division of Vascular Medicine, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland

,

Drahomir Aujesky

³Division of General Internal Medicine, Bern University Hospital, Bern, Switzerland

,

Jürg H. Beer

⁴Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland

,

Thomas Baldi

⁵Department of Internal Medicine, University Hospital Basel, Basel, Switzerland

,

Martin Banyai

⁶Department of Internal Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland

,

Daniel Hayoz

⁷Department of Internal Medicine, Cantonal Hospital Fribourg, Fribourg, Switzerland

,

Thomas Kaeslin

⁸Department of Internal Medicine, Cantonal Hospital Obwalden, Sarnen, Switzerland

,

Wolfgang Korte

⁹Department of Internal Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

,

Robert Escher

¹⁰Department of Internal Medicine, Regional Hospital Burgdorf, Burgdorf, Switzerland

,

Marc Husmann

¹¹Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

,

Beat Frauchiger

¹²Department of Internal Medicine, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland

,

Rolf P. Engelberger

²Division of Vascular Medicine, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland

⁷Department of Internal Medicine, Cantonal Hospital Fribourg, Fribourg, Switzerland

,

Iris Baumgartner

²Division of Vascular Medicine, Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland

,

David Spirk

¹³Institute of Pharmacology, University of Bern, Bern, Switzerland

› Institutsangaben

Abstract

The modified Ottawa score (MOS) predicted venous thromboembolism (VTE) recurrence in a cohort of patients with cancer-associated thrombosis mainly managed on an outpatient basis. We aimed to assess the prognostic value of the MOS in hospitalized patients with cancer-associated thrombosis. In 383 hospitalized patients with cancer-associated VTE from the SWIss VTE Registry, 98 (25%) were classified as low risk, 175 (46%) as intermediate risk, and 110 (29%) as high risk for VTE recurrence based on the MOS. Clinical end points were recurrent VTE, fatal VTE, major bleeding, and overall mortality at 90 days. Overall, 179 (47%) patients were female, 172 (45%) had metastatic disease, and 72 (19%) prior VTE. The primary site of cancer was lung in 48 (13%) patients and breast in 43 (11%). According to the MOS, the rate of VTE recurrence was 4.1% for low, 6.3% intermediate, and 5.5% high risk (p = 0.75); the rate of fatal VTE was 0.8, 1.9, and 2.0% (p = 0.69); the rate of major bleeding was 3.1, 4.1, and 3.6% (p = 0.92); and the rate of death was 6.1, 12.0, and 28.2% (p < 0.001), respectively. None of the MOS items was associated with VTE recurrence: female gender hazard ratio (HR) 1.26 (95% confidence interval [CI], 0.53–2.96), lung cancer HR 1.17 (95% CI, 0.35–3.98), prior VTE HR 0.44 (95% CI, 0.10–1.91), breast cancer HR 0.83 (95% CI, 0.19–3.58), and absence of metastases HR 0.74 (95% CI, 0.31–1.74). In hospitalized patients with cancer-associated VTE, the MOS failed to predict VTE recurrence at 3 months but was associated with early mortality.

Keywords

cancer - mortality - modified Ottawa score - venous thromboembolism

Volltext

Referenzen

References
1 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (06) 715-722
2 Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009; 22 (01) 9-23
3 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
4 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
5 Akl EA, Kahale L, Barba M. , et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; (07) CD006650
6 Carrier M, Lazo-Langner A, Shivakumar S. , et al. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol 2015; 22 (01) 49-59
7 Louzada ML, Carrier M, Lazo-Langner A. , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
8 den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 2013; 11 (05) 998-1000
9 Khorana AA, Bauersachs R, Kamphuisen PW. , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study. J Clin Oncol 2015; 33 (Suppl 1; 9621): 533s
10 Spirk D, Aujesky D, Stuck AK. , et al. Clinical outcomes of venous thromboembolism in patients with and without cancer: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Semin Thromb Hemost 2016; 42 (06) 642-649
11 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
12 Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Support Care Cancer 2013; 21 (08) 2309-2313
13 Astruc N, Ianotto JC, Metges JP, Lacut K, Delluc A. External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis. Eur J Intern Med 2016; 36: e11-e12
14 Maestre A, Sánchez R, Rosa V. , et al; RIETE Investigators. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry. Eur J Intern Med 2010; 21 (05) 377-382
15 Young A, Phillips J, Hancocks H. , et al. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 2016; 140 (Suppl. 01) S172-S173
16 van Es N, Di Nisio M, Bleker SM. , et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114 (06) 1268-1276
17 Bach M, Bauersachs R. Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE. Thromb Haemost 2016; 116 (Suppl. 02) S24-S32
18 Trujillo-Santos J, Nieto JA, Tiberio G. , et al; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (03) 435-439